Bio-Rad Laboratories, Inc. logo
Bio-Rad Laboratories, Inc. (BIO)
Compare

Bio-Rad Laboratories, Inc. (BIO) EV/EBITDA Ratio: 254.89x

Is Bio-Rad Laboratories, Inc.’s EV/EBITDA ratio high or low?

Bio-Rad Laboratories, Inc.'s EV/EBITDA ratio of 254.89x is 428% above its 5-year average of 48.31x, near the high end of its 5-year range (1.88x–273.11x).

The EV/EBITDA ratio for Bio-Rad Laboratories, Inc. (BIO) is 254.89x as of Thursday, June 11, 2026. It is above its 12-month average by 330.03% (59.27x).

BIO EV/EBITDA Ratio Chart

BIO EV/EBITDA Ratio
254.89x+2194.24% 1Y
Zoom

BIO Average EV/EBITDA Ratio Chart

BIO Current vs Average EV/EBITDA Ratio Chart

BIO EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

254.89x

EV/EBITDA RATIO AVG TTM

59.27x

EV/EBITDA RATIO AVG 3Y

93.59x

EV/EBITDA RATIO AVG 5Y

48.31x

EV/EBITDA RATIO AVG 10Y

24.06x

EV/EBITDA RATIO AVG 15Y

18.23x

EV/EBITDA RATIO AVG 20Y

15.83x

CURRENT VS TTM AVG

+330.03%

CURRENT VS 3Y AVG

+172.35%

CURRENT VS 5Y AVG

+427.65%

CURRENT VS 10Y AVG

+959.34%

CURRENT VS 15Y AVG

+1298.48%

CURRENT VS 20Y AVG

+1509.83%

BIO Competitors' EV/EBITDA Ratio

NAMEMARKET CAPEV/EBITDA RATIOTTM3Y5Y
Bio-Rad Laboratories, Inc. (BIO)$7.92B254.89x59.27x93.59x48.31x
Charles River Laboratories International, Inc. (CRL)$8.94B14.86x19.01x15.54x17.40x
Hims & Hers Health, Inc. (HIMS)$6.42B74.96x67.13x332.36x332.36x
Baxter International Inc. (BAX)$10.49B24.37x20.31x19.09x19.10x
Align Technology, Inc. (ALGN)$12.27B13.98x13.90x20.40x25.86x
Hologic, Inc. (HOLX)$16.97B17.28x15.01x15.35x12.41x
Moderna, Inc. (MRNA)$18.71BN/A12.39x25.27x25.27x
BioNTech SE (BNTX)$21.92BN/A51.40x19.63x20.05x
Mettler-Toledo International Inc. (MTD)$22.82B20.23x23.55x23.87x26.49x
Waters Corporation (WAT)$23.60B37.66x21.66x21.26x21.46x

EV/EBITDA vs. its own history

At 254.9, EV/EBITDA is richer than usual — richer than 100% of its 20-year range.

20-year low

1.9

median

10.2

20-year high

273.1

cheaperricher

Understanding EV/EBITDA

Enterprise Value (EV) = Market Cap + Total Debt - Cash

EBITDA = Earnings Before Interest, Taxes, Depreciation & Amortization

EV/EBITDA is commonly used for comparing companies because:

  • It accounts for debt levels (capital structure neutral)
  • It removes effects of different depreciation policies
  • It can be compared across countries with different tax rates
  • It can remain available when net income is negative, if EBITDA is positive

Bio-Rad Laboratories, Inc. EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Bio-Rad Laboratories, Inc. EV/EBITDA Ratio FAQ

What is the EV/EBITDA ratio for Bio-Rad Laboratories, Inc. (BIO)?
The EV/EBITDA ratio for BIO stock is 254.89x.
Is Bio-Rad Laboratories, Inc.'s EV/EBITDA ratio high or low?
Bio-Rad Laboratories, Inc.'s EV/EBITDA ratio of 254.89x is 428% above its 5-year average of 48.31x, near the high end of its 5-year range (1.88x–273.11x).
What is the TTM average EV/EBITDA ratio for Bio-Rad Laboratories, Inc. (BIO)?
The TTM average EV/EBITDA ratio for BIO stock is 59.27x.
What is the 3Y average EV/EBITDA ratio for Bio-Rad Laboratories, Inc. (BIO)?
The 3Y average EV/EBITDA ratio for BIO stock is 93.59x.
What is the 5Y average EV/EBITDA ratio for Bio-Rad Laboratories, Inc. (BIO)?
The 5Y average EV/EBITDA ratio for BIO stock is 48.31x.
What is the 10Y average EV/EBITDA ratio for Bio-Rad Laboratories, Inc. (BIO)?
The 10Y average EV/EBITDA ratio for BIO stock is 24.06x.
What is the 15Y average EV/EBITDA ratio for Bio-Rad Laboratories, Inc. (BIO)?
The 15Y average EV/EBITDA ratio for BIO stock is 18.23x.
What is the 20Y average EV/EBITDA ratio for Bio-Rad Laboratories, Inc. (BIO)?
The 20Y average EV/EBITDA ratio for BIO stock is 15.83x.

Bio-Rad Laboratories, Inc. EV/EBITDA Ratio History

DATEEV/EBITDA RATIO
2026-06-11254.89x
2026-06-10251.91x
2026-06-09256.71x
2026-06-08252.14x
2026-06-05254.49x
2026-06-04264.73x
2026-06-03262.68x
2026-06-02263.69x
2026-06-01263.17x
2026-05-29268.64x
2026-05-28273.11x
2026-05-27263.03x
2026-05-26256.50x
2026-05-22249.36x
2026-05-21248.58x
2026-05-20249.45x
2026-05-19244.15x
2026-05-18244.75x
2026-05-15218.03x
2026-05-14217.05x
2026-05-13214.90x
2026-05-12213.50x
2026-05-11215.12x
2026-05-08223.32x
2026-05-07225.66x
2026-05-06226.98x
2026-05-05225.50x
2026-05-04226.08x
2026-05-01225.06x
2026-04-30243.42x
2026-04-299.97x
2026-04-2810.10x
2026-04-2710.36x
2026-04-2410.38x
2026-04-2310.17x
2026-04-2210.79x
2026-04-2110.95x
2026-04-2010.87x
2026-04-1710.73x
2026-04-1610.48x
2026-04-1510.64x
2026-04-1410.52x
2026-04-1310.39x
2026-04-1010.10x
2026-04-0910.05x
2026-04-0810.16x
2026-04-0710.06x
2026-04-0610.09x
2026-04-0210.13x
2026-04-0110.07x
2026-03-3110.09x
2026-03-309.82x
2026-03-279.66x
2026-03-2610.02x
2026-03-259.92x
2026-03-249.87x
2026-03-239.65x
2026-03-209.63x
2026-03-199.65x
2026-03-189.74x
2026-03-179.79x
2026-03-169.53x
2026-03-139.58x
2026-03-129.55x
2026-03-119.80x
2026-03-109.74x
2026-03-099.85x
2026-03-069.80x
2026-03-0510.10x
2026-03-0410.28x
2026-03-0310.13x
2026-03-0210.11x
2026-02-2710.08x
2026-02-269.97x
2026-02-259.80x
2026-02-249.77x
2026-02-239.75x
2026-02-209.85x
2026-02-199.87x
2026-02-189.83x
2026-02-179.64x
2026-02-139.38x
2026-02-1210.52x
2025-10-2814.62x
2025-10-2714.85x
2025-10-2414.99x
2025-10-2314.95x
2025-10-2214.76x
2025-10-2114.66x
2025-10-2014.28x
2025-10-1713.81x
2025-10-1613.91x
2025-10-1513.65x
2025-10-1413.62x
2025-10-1313.56x
2025-10-1013.32x
2025-10-0913.44x
2025-10-0813.53x
2025-10-0713.28x
2025-10-0613.78x
2025-10-0313.63x
2025-10-0213.19x
2025-10-0113.33x
2025-09-3012.64x
2025-09-2912.23x
2025-09-2612.28x
2025-09-2512.24x
2025-09-2412.49x
2025-09-2312.70x
2025-09-2212.76x
2025-09-1912.78x
2025-09-1812.88x
2025-09-1712.63x
2025-09-1612.71x
2025-09-1512.63x
2025-09-1212.64x
2025-09-1112.86x
2025-09-1012.50x
2025-09-0912.86x
2025-09-0813.03x
2025-09-0513.23x
2025-09-0413.00x
2025-09-0312.94x
2025-09-0213.05x
2025-08-2913.33x
2025-08-2813.16x
2025-08-2713.13x
2025-08-2613.28x
2025-08-2513.31x
2025-08-2213.57x
2025-08-2112.82x
2025-08-2012.95x
2025-08-1912.95x
2025-08-1812.81x
2025-08-1512.85x
2025-08-1412.91x
2025-08-1312.91x
2025-08-1212.41x
2025-08-1112.01x
2025-08-0812.00x
2025-08-0712.04x
2025-08-0612.00x
2025-08-0512.31x
2025-08-0412.49x
2025-08-0112.80x
2025-07-3111.11x
2024-02-15167.75x
2024-02-14167.37x
2024-02-13161.88x
2024-02-12166.62x
2024-02-09166.12x
2024-02-08166.53x
2024-02-07166.09x
2024-02-06166.02x
2024-02-05163.10x
2024-02-02163.89x
2024-02-01167.86x
2024-01-31164.11x
2024-01-30169.46x
2024-01-29168.36x
2024-01-26167.90x
2024-01-25161.98x
2024-01-24162.10x
2024-01-23161.49x
2024-01-22160.37x
2024-01-19157.48x
2024-01-18156.31x
2024-01-17156.32x
2024-01-16161.47x
2024-01-12163.03x
2024-01-11164.08x
2024-01-10164.05x
2024-01-09162.66x
2024-01-08164.61x
2024-01-05162.01x
2024-01-04162.06x
2024-01-03163.16x
2024-01-02167.41x
2023-12-29165.04x
2023-12-28165.84x
2023-12-27164.69x
2023-12-26164.13x
2023-12-22164.04x
2023-12-21163.49x
2023-12-20158.26x
2023-12-19161.45x
2023-12-18158.09x
2023-12-15157.25x
2023-12-14159.97x
2023-12-13161.03x
2023-12-12151.97x
2023-12-11156.29x
2023-12-08156.32x
2023-12-07159.13x
2023-12-06159.39x
2023-12-05157.09x
2023-12-04158.55x
2023-12-01157.66x
2023-11-30156.69x
2023-11-29156.49x
2023-11-28156.45x
2023-11-27157.72x
2023-11-24159.60x
2023-11-22158.99x
2023-11-21157.28x
2023-11-20156.50x
2023-11-17154.11x
2023-11-16156.49x
2023-11-15157.60x
2023-11-14157.88x
2023-11-13156.15x
2023-11-10156.28x
2023-11-09157.55x
2023-11-08156.79x
2023-11-07155.71x
2023-11-06149.23x
2023-11-03148.78x
2023-11-02145.67x
2023-11-01143.95x
2023-10-31142.92x
2023-10-30140.18x
2023-10-27140.79x
2022-04-282.70x
2022-04-272.63x
2022-04-262.59x
2022-04-252.79x
2022-04-222.81x
2022-04-212.87x
2022-04-202.96x
2022-04-192.93x
2022-04-182.85x
2022-04-142.88x
2022-04-132.97x
2022-04-122.94x
2022-04-113.11x
2022-04-083.15x
2022-04-073.14x
2022-04-063.04x
2022-04-053.03x
2022-04-043.00x
2022-04-013.00x
2022-03-312.96x
2022-03-303.05x
2022-03-293.06x
2022-03-283.02x
2022-03-252.97x
2022-03-242.99x
2022-03-232.98x
2022-03-223.10x
2022-03-213.05x
2022-03-183.10x
2022-03-173.03x
2022-03-162.96x
2022-03-152.89x
2022-03-142.85x
2022-03-112.79x
2022-03-102.85x
2022-03-092.92x
2022-03-082.76x
2022-03-072.89x

Showing the most recent 260 of 4,221 data points. The chart above shows the full history.

About Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.

Hercules, CA
7,700 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Norman D. Schwartz